Needham & Company Reiterates a 'Buy' on Seattle Genetics (SGEN); Raising Price Target After ASCO Meeting Review
Tweet Send to a FriendGet Alerts SGEN Hot Sheet
Price: $35.35 +0.57%
Rating Summary:
5 Buy, 5 Hold, 10 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 21 | Down: 24 | New: 29
Rating Summary:
5 Buy, 5 Hold, 10 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 21 | Down: 24 | New: 29
Trade SGEN Now!
Needham & Company reiterates a 'Buy' on Seattle Genetics (NASDAQ: SGEN) price target of $25.00 (from $20.00).
Analyst, Alan Carr, said, "Data from three ongoing company-sponsored Adcetris clinical trials were presented at the ASCO meeting earlier this week. Results from a Phase 2 retreatment trial indicate physicians can return to the drug and expect efficacy comparable to initial treatment. Encouraging signs of efficacy were seen in the first interim analysis of a Phase 2 trial in CD30+ r/r NHL patients, including r/r DLBCL (4/7 OR). Preliminary data from a large CD30 screening effort in patients with nonlymphomatous tumors suggests that CD30 prevalence is ~2%, with potential enrichment in mesothelioma and melanoma, among others."
For an analyst ratings summary and ratings history on Seattle Genetics click here. For more ratings news on Seattle Genetics click here.
Shares of Seattle Genetics closed at $22.41 yesterday, with a 52 week range of $12.29-$22.55.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Alan Carr, said, "Data from three ongoing company-sponsored Adcetris clinical trials were presented at the ASCO meeting earlier this week. Results from a Phase 2 retreatment trial indicate physicians can return to the drug and expect efficacy comparable to initial treatment. Encouraging signs of efficacy were seen in the first interim analysis of a Phase 2 trial in CD30+ r/r NHL patients, including r/r DLBCL (4/7 OR). Preliminary data from a large CD30 screening effort in patients with nonlymphomatous tumors suggests that CD30 prevalence is ~2%, with potential enrichment in mesothelioma and melanoma, among others."
For an analyst ratings summary and ratings history on Seattle Genetics click here. For more ratings news on Seattle Genetics click here.
Shares of Seattle Genetics closed at $22.41 yesterday, with a 52 week range of $12.29-$22.55.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Hewlett-Packard (HPQ) Q2 Performance Wins Praise on Wall Street; Jefferies Raises to Hold
- Compuware (CPWR) Estimates Trimmed, PT Raised at Jefferies
- Canaccord Genuity Boosts Price Target on Akamai (AKAM) Citing Momentum
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
Needham & Company
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
